Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine
David W. Dodick(New York Academy of Medicine), Eric Pearlman(University of California, San Francisco), Virginia L. Stauffer(Eli Lilly (United States)), Jakub Jedynak(Eli Lilly (United States)), Sheena K. Aurora(Impel Neuropharma (United States)), Erin Doty(Eli Lilly (United States)), Dustin Ruff(Eli Lilly (United States)), Yanhong Dong(National University of Singapore)
Cited by 106
Related Papers
A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease
|Annals of Neurology|1999|890
Targeted Disruption of the Chemokine Eotaxin Partially Reduces Antigen-induced Tissue Eosinophilia
|The Journal of Experimental Medicine|1997|532
CGRP and the Trigeminal System in Migraine
|Headache The Journal of Head and Face Pain|2019|483
N-GSDMD trafficking to neutrophil organelles facilitates IL-1β release independently of plasma membrane pores and pyroptosis
|Nature Communications|2020|453
Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1β secretion in response to ATP
|Nature Communications|2016|446